-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, N6xaCW/B3XjftzwmvNdGURfW2RkCfp91TeAdipKR3IPMuMYDl5/Aoo0i7v5IQAZN Y5Gn8WMNZLaqP2SkElosqA== 0000950129-02-002508.txt : 20020514 0000950129-02-002508.hdr.sgml : 20020514 ACCESSION NUMBER: 0000950129-02-002508 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020514 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CADUS PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0000911148 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 133660391 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-46485 FILM NUMBER: 02647016 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591-6705 BUSINESS PHONE: 9143453344 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591-6705 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PHYSICA B V CENTRAL INDEX KEY: 0001019976 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: C J VAN HOUTELAND 36 STREET 2: 1381 CP WEEAP CITY: NETHERLANDS BUSINESS PHONE: 2127585106 MAIL ADDRESS: STREET 1: CJ VAN HOUSTENLAAN 36 STREET 2: 1381 CP WEEAP CITY: NETHERLANDS FORMER COMPANY: FORMER CONFORMED NAME: PHYSICS B V DATE OF NAME CHANGE: 19960729 SC 13D/A 1 h96591sc13da.txt PHYSICA B.V. FOR CADUS PHARMACEUTICAL CORPORATION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) (AMENDMENT NO. 1) 1 Cadus Pharmaceutical Corporation ------------------------------------ (Name of Issuer) Common Stock, $0.01 par value ---------------------------------------- (Title of Class of Securities) 127639-10-2 ---------------- (CUSIP Number) E.J. Buckingham, III, Esq. Solvay America, Inc. 3333 Richmond Avenue Houston, Texas 77098 (713) 525-6080 ------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) April 23, 2002 ------------------------- (Date of Event which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. [ ] Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent. (Continued on following pages) (Page 1 of 5 Pages) - ----------- (1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2
- ------------------------------- -------------------------------- CUSIP NO. 127639 10 2 13D PAGE 2 OF 5 PAGES - ------------------------------- -------------------------------- - -------------------------------------------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Physica B.V. - -------------------------------------------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP * (a) [ ] (b) [X] - -------------------------------------------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------------------------------------------- 4 SOURCE OF FUNDS * Not applicable - -------------------------------------------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) [ ] - -------------------------------------------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION The Netherlands - -------------------------------------------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF 0 SHARES ----------------------------------------------------------------------------------------- BENEFICIALLY OWNED BY 8 SHARED VOTING POWER EACH 0 REPORTING ------------------------------------------------------------------------------------------ PERSON 9 SOLE DISPOSITIVE POWER WITH 0 ------------------------------------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER 0 - -------------------------------------------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 - -------------------------------------------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES * [ ] - -------------------------------------------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.0% - -------------------------------------------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON * CO - --------------------------------------------------------------------------------------------------------------------
2 ITEM 1. SECURITY AND ISSUER. This Schedule 13D/A ("Schedule 13D/A") relates to the beneficial ownership of shares of common stock, par value $0.01 per share (the "Common Stock"), of Cadus Pharmaceutical Corporation, a Delaware corporation (the "Company"). The address of the principal executive office of Cadus is 767 Fifth Avenue, New York, New York 10153. ITEM 2. IDENTITY AND BACKGROUND. Physica B.V. ("Physica") is a Dutch corporation that is in the business of forwarding, including but not limited to pharmaceutical, chemical, biological, and mechanical products. Its principal business address and the address of its principal office is C.J. van Houtenlaan 36, 1381 CP Weesp, The Netherlands. Physica has no directors. Physica's sole officer is Egidius Aloysius Alphonsus Maria Koopmans, who is President and CEO. No director or officer of Physica has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years. No director or officer of Physica was, during the last five years, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. Not applicable. ITEM 4. PURPOSE OF TRANSACTION. Sale of all shares of Common Stock held by Physica. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. (a) None. (b) Not applicable. (c) All shares of Common Stock that were beneficially owned by Physica were sold, pursuant to a Stock Purchase Agreement, dated April 23, 2002, to Barberry Corp. (d) Not applicable. 3 (e) Pursuant to the terms of the Stock Purchase Agreement, all shares of Common Stock held by Physica were transferred on April 23, 2002, and Physica ceased to be the beneficial owner of any shares of Common Stock on that date. ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER. None. ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. None. 4 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct. May 14, 2002 /s/ E.A.A.M. Koopmans - ------------------ ------------------------------------------------- (Date) Egidius Aloysius Alphonsus Maria Koopmans President and CEO 5 -----END PRIVACY-ENHANCED MESSAGE-----